CLARIVATE PLC (Form: 10-Q, Received: 07/30/2025 06:10:26)

0001764046falseDecember 312025Q200-0000000http://fasb.org/us-gaap/2025#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2025#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilitieshttp://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilitiesxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesclvt:segmentclvt:swapiso4217:EURxbrli:pure00017640462025-01-012025-06-3000017640462025-06-3000017640462024-12-3100017640462025-04-012025-06-3000017640462024-04-012024-06-3000017640462024-01-012024-06-300001764046us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-12-310001764046us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001764046us-gaap:RetainedEarningsMember2024-12-310001764046us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-01-012025-03-3100017640462025-01-012025-03-310001764046us-gaap:RetainedEarningsMember2025-01-012025-03-310001764046us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001764046us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-03-310001764046us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001764046us-gaap:RetainedEarningsMember2025-03-3100017640462025-03-310001764046us-gaap:CommonStockMember2025-04-012025-06-300001764046us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-04-012025-06-300001764046us-gaap:RetainedEarningsMember2025-04-012025-06-300001764046us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001764046us-gaap:CommonStockMember2025-06-300001764046us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-06-300001764046us-gaap:PreferredStockMember2025-06-300001764046us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001764046us-gaap:RetainedEarningsMember2025-06-300001764046us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-12-310001764046us-gaap:PreferredStockMember2023-12-310001764046us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001764046us-gaap:RetainedEarningsMember2023-12-3100017640462023-12-310001764046us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-01-012024-03-3100017640462024-01-012024-03-310001764046us-gaap:RetainedEarningsMember2024-01-012024-03-310001764046us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001764046us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-03-310001764046us-gaap:PreferredStockMember2024-03-310001764046us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001764046us-gaap:RetainedEarningsMember2024-03-3100017640462024-03-310001764046us-gaap:CommonStockMember2024-04-012024-06-300001764046us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-04-012024-06-300001764046us-gaap:PreferredStockMember2024-04-012024-06-300001764046us-gaap:RetainedEarningsMember2024-04-012024-06-300001764046us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001764046us-gaap:CommonStockMember2024-06-300001764046us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-06-300001764046us-gaap:PreferredStockMember2024-06-300001764046us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001764046us-gaap:RetainedEarningsMember2024-06-3000017640462024-06-300001764046clvt:SubscriptionRevenuesMember2025-04-012025-06-300001764046clvt:SubscriptionRevenuesMember2024-04-012024-06-300001764046clvt:SubscriptionRevenuesMember2025-01-012025-06-300001764046clvt:SubscriptionRevenuesMember2024-01-012024-06-300001764046clvt:ReOccurringRevenuesMember2025-04-012025-06-300001764046clvt:ReOccurringRevenuesMember2024-04-012024-06-300001764046clvt:ReOccurringRevenuesMember2025-01-012025-06-300001764046clvt:ReOccurringRevenuesMember2024-01-012024-06-300001764046clvt:TransactionalRevenuesMember2025-04-012025-06-300001764046clvt:TransactionalRevenuesMember2024-04-012024-06-300001764046clvt:TransactionalRevenuesMember2025-01-012025-06-300001764046clvt:TransactionalRevenuesMember2024-01-012024-06-300001764046us-gaap:CustomerRelationshipsMember2025-06-300001764046us-gaap:CustomerRelationshipsMember2024-12-310001764046clvt:DatabasesAndContentMember2025-06-300001764046clvt:DatabasesAndContentMember2024-12-310001764046us-gaap:ComputerSoftwareIntangibleAssetMember2025-06-300001764046us-gaap:ComputerSoftwareIntangibleAssetMember2024-12-310001764046us-gaap:OtherIntangibleAssetsMember2025-06-300001764046us-gaap:OtherIntangibleAssetsMember2024-12-310001764046us-gaap:TradeNamesMember2025-06-300001764046us-gaap:TradeNamesMember2024-12-310001764046clvt:InterestRateSwapMaturingOctober2026Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2025-06-300001764046clvt:InterestRateSwapMaturingJanuary2031Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2025-06-300001764046us-gaap:InterestRateSwapMember2025-01-012025-06-300001764046us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMember2025-06-300001764046us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2025-06-300001764046us-gaap:ForeignExchangeContractMembersrt:MaximumMember2025-04-012025-06-300001764046us-gaap:ForeignExchangeContractMember2025-06-300001764046us-gaap:ForeignExchangeContractMember2024-12-310001764046us-gaap:ForeignExchangeContractMember2025-04-012025-06-300001764046us-gaap:ForeignExchangeContractMember2024-04-012024-06-300001764046us-gaap:ForeignExchangeContractMember2025-01-012025-06-300001764046us-gaap:ForeignExchangeContractMember2024-01-012024-06-300001764046us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-06-300001764046us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310001764046us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-06-300001764046us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310001764046us-gaap:CurrencySwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMember2025-06-300001764046us-gaap:CurrencySwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMember2024-12-310001764046us-gaap:CurrencySwapMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-06-300001764046us-gaap:CurrencySwapMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310001764046us-gaap:CurrencySwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2025-06-300001764046us-gaap:CurrencySwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2024-12-310001764046us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2025-06-300001764046us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-12-310001764046us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2025-06-300001764046us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2024-12-310001764046clvt:SeniorSecuredNotes2026Member2025-06-300001764046clvt:SeniorSecuredNotes2026Member2024-12-310001764046clvt:SeniorSecuredNotes2028Member2025-06-300001764046clvt:SeniorSecuredNotes2028Member2024-12-310001764046clvt:SeniorNotes2029Member2025-06-300001764046clvt:SeniorNotes2029Member2024-12-310001764046us-gaap:RevolvingCreditFacilityMember2025-06-300001764046us-gaap:RevolvingCreditFacilityMember2024-12-310001764046clvt:TermLoanFacilityTranche1Member2025-06-300001764046clvt:TermLoanFacilityTranche1Member2024-12-310001764046clvt:TermLoanFacilityTranche2Member2025-06-300001764046clvt:SeniorSecuredNotes2026Member2025-05-012025-05-310001764046us-gaap:LetterOfCreditMember2025-06-300001764046us-gaap:RevolvingCreditFacilityMember2025-06-300001764046clvt:TermLoanFacilityTranche1Memberus-gaap:SecuredDebtMember2024-01-310001764046clvt:TermLoanFacilityTranche1Memberus-gaap:SecuredDebtMember2024-01-012024-01-310001764046clvt:TermLoanFacilityTranche2Memberus-gaap:SecuredDebtMember2025-05-310001764046clvt:TermLoanFacilityTranche2Memberus-gaap:SecuredDebtMember2025-05-012025-05-310001764046us-gaap:FairValueInputsLevel2Member2025-06-300001764046us-gaap:FairValueInputsLevel2Member2024-12-3100017640462023-05-310001764046us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310001764046us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310001764046us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310001764046us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-06-300001764046us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-06-300001764046us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-06-300001764046us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-06-300001764046us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-06-300001764046us-gaap:AccumulatedTranslationAdjustmentMember2025-06-300001764046us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001764046us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310001764046us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001764046us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-06-300001764046us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-06-300001764046us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-06-300001764046us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-06-300001764046us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300001764046us-gaap:AccumulatedTranslationAdjustmentMember2024-06-3000017640462024-06-032024-06-030001764046clvt:ValueCreationPlanMember2025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:ValueCreationPlanMember2025-04-012025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:ValueCreationPlanMember2024-04-012024-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:ValueCreationPlanMember2025-01-012025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:ValueCreationPlanMember2024-01-012024-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:SegmentOptimizationProgramMember2025-04-012025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:SegmentOptimizationProgramMember2024-04-012024-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:SegmentOptimizationProgramMember2025-01-012025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:SegmentOptimizationProgramMember2024-01-012024-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:ProQuestAcquisitionIntegrationProgramMember2025-04-012025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:ProQuestAcquisitionIntegrationProgramMember2024-04-012024-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:ProQuestAcquisitionIntegrationProgramMember2025-01-012025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMemberclvt:ProQuestAcquisitionIntegrationProgramMember2024-01-012024-06-300001764046clvt:SeveranceAndRelatedBenefitCostMember2025-04-012025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMember2024-04-012024-06-300001764046clvt:SeveranceAndRelatedBenefitCostMember2025-01-012025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMember2024-01-012024-06-300001764046clvt:ExitAndDisposalCostsMemberclvt:ValueCreationPlanMember2025-04-012025-06-300001764046clvt:ExitAndDisposalCostsMemberclvt:ValueCreationPlanMember2024-04-012024-06-300001764046clvt:ExitAndDisposalCostsMemberclvt:ValueCreationPlanMember2025-01-012025-06-300001764046clvt:ExitAndDisposalCostsMemberclvt:ValueCreationPlanMember2024-01-012024-06-300001764046clvt:ExitAndDisposalCostsMemberclvt:SegmentOptimizationProgramMember2025-04-012025-06-300001764046clvt:ExitAndDisposalCostsMemberclvt:SegmentOptimizationProgramMember2024-04-012024-06-300001764046clvt:ExitAndDisposalCostsMemberclvt:SegmentOptimizationProgramMember2025-01-012025-06-300001764046clvt:ExitAndDisposalCostsMemberclvt:SegmentOptimizationProgramMember2024-01-012024-06-300001764046clvt:ExitAndDisposalCostsMember2025-04-012025-06-300001764046clvt:ExitAndDisposalCostsMember2024-04-012024-06-300001764046clvt:ExitAndDisposalCostsMember2025-01-012025-06-300001764046clvt:ExitAndDisposalCostsMember2024-01-012024-06-300001764046clvt:LeaseAbandonmentCostsMemberclvt:SegmentOptimizationProgramMember2025-04-012025-06-300001764046clvt:LeaseAbandonmentCostsMemberclvt:SegmentOptimizationProgramMember2024-04-012024-06-300001764046clvt:LeaseAbandonmentCostsMemberclvt:SegmentOptimizationProgramMember2025-01-012025-06-300001764046clvt:LeaseAbandonmentCostsMemberclvt:SegmentOptimizationProgramMember2024-01-012024-06-300001764046clvt:LeaseAbandonmentCostsMember2025-04-012025-06-300001764046clvt:LeaseAbandonmentCostsMember2024-04-012024-06-300001764046clvt:LeaseAbandonmentCostsMember2025-01-012025-06-300001764046clvt:LeaseAbandonmentCostsMember2024-01-012024-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:ValueCreationPlanMember2025-04-012025-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:ValueCreationPlanMember2024-04-012024-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:ValueCreationPlanMember2025-01-012025-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:ValueCreationPlanMember2024-01-012024-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:SegmentOptimizationProgramMember2025-04-012025-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:SegmentOptimizationProgramMember2024-04-012024-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:SegmentOptimizationProgramMember2025-01-012025-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:SegmentOptimizationProgramMember2024-01-012024-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:ProQuestAcquisitionIntegrationProgramMember2025-04-012025-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:ProQuestAcquisitionIntegrationProgramMember2024-04-012024-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:ProQuestAcquisitionIntegrationProgramMember2025-01-012025-06-300001764046clvt:AcademiaGovernmentGroupMemberclvt:ProQuestAcquisitionIntegrationProgramMember2024-01-012024-06-300001764046clvt:AcademiaGovernmentGroupMember2025-04-012025-06-300001764046clvt:AcademiaGovernmentGroupMember2024-04-012024-06-300001764046clvt:AcademiaGovernmentGroupMember2025-01-012025-06-300001764046clvt:AcademiaGovernmentGroupMember2024-01-012024-06-300001764046clvt:IntellectualPropertyGroupMemberclvt:ValueCreationPlanMember2025-04-012025-06-300001764046clvt:IntellectualPropertyGroupMemberclvt:ValueCreationPlanMember2024-04-012024-06-300001764046clvt:IntellectualPropertyGroupMemberclvt:ValueCreationPlanMember2025-01-012025-06-300001764046clvt:IntellectualPropertyGroupMemberclvt:ValueCreationPlanMember2024-01-012024-06-300001764046clvt:IntellectualPropertyGroupMemberclvt:SegmentOptimizationProgramMember2025-04-012025-06-300001764046clvt:IntellectualPropertyGroupMemberclvt:SegmentOptimizationProgramMember2024-04-012024-06-300001764046clvt:IntellectualPropertyGroupMemberclvt:SegmentOptimizationProgramMember2025-01-012025-06-300001764046clvt:IntellectualPropertyGroupMemberclvt:SegmentOptimizationProgramMember2024-01-012024-06-300001764046clvt:IntellectualPropertyGroupMember2025-04-012025-06-300001764046clvt:IntellectualPropertyGroupMember2024-04-012024-06-300001764046clvt:IntellectualPropertyGroupMember2025-01-012025-06-300001764046clvt:IntellectualPropertyGroupMember2024-01-012024-06-300001764046clvt:LifeSciencesAndHealthcareGroupMemberclvt:ValueCreationPlanMember2025-04-012025-06-300001764046clvt:LifeSciencesAndHealthcareGroupMemberclvt:ValueCreationPlanMember2024-04-012024-06-300001764046clvt:LifeSciencesAndHealthcareGroupMemberclvt:ValueCreationPlanMember2025-01-012025-06-300001764046clvt:LifeSciencesAndHealthcareGroupMemberclvt:ValueCreationPlanMember2024-01-012024-06-300001764046clvt:LifeSciencesAndHealthcareGroupMemberclvt:SegmentOptimizationProgramMember2025-04-012025-06-300001764046clvt:LifeSciencesAndHealthcareGroupMemberclvt:SegmentOptimizationProgramMember2024-04-012024-06-300001764046clvt:LifeSciencesAndHealthcareGroupMemberclvt:SegmentOptimizationProgramMember2025-01-012025-06-300001764046clvt:LifeSciencesAndHealthcareGroupMemberclvt:SegmentOptimizationProgramMember2024-01-012024-06-300001764046clvt:LifeSciencesAndHealthcareGroupMember2025-04-012025-06-300001764046clvt:LifeSciencesAndHealthcareGroupMember2024-04-012024-06-300001764046clvt:LifeSciencesAndHealthcareGroupMember2025-01-012025-06-300001764046clvt:LifeSciencesAndHealthcareGroupMember2024-01-012024-06-300001764046clvt:SeveranceAndRelatedBenefitCostMember2024-12-310001764046clvt:ExitDisposalAndAbandonmentCostsMember2024-12-310001764046clvt:ExitDisposalAndAbandonmentCostsMember2025-01-012025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMember2025-06-300001764046clvt:ExitDisposalAndAbandonmentCostsMember2025-06-300001764046clvt:SeveranceAndRelatedBenefitCostMember2023-12-310001764046clvt:ExitDisposalAndAbandonmentCostsMember2023-12-310001764046clvt:ExitDisposalAndAbandonmentCostsMember2024-01-012024-06-300001764046clvt:SeveranceAndRelatedBenefitCostMember2024-06-300001764046clvt:ExitDisposalAndAbandonmentCostsMember2024-06-300001764046us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberclvt:MarkMonitorMember2025-04-012025-06-300001764046us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberclvt:MarkMonitorMember2024-04-012024-06-300001764046us-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-01-012024-06-300001764046clvt:WarrantAndShareBasedPaymentArrangementMember2025-04-012025-06-300001764046clvt:WarrantAndShareBasedPaymentArrangementMember2024-04-012024-06-300001764046clvt:WarrantAndShareBasedPaymentArrangementMember2025-01-012025-06-300001764046clvt:WarrantAndShareBasedPaymentArrangementMember2024-01-012024-06-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _______

Commission File No. 001-38911

CLARIVATE PLC

(Exact name of registrant as specified in its charter)


Jersey, Channel Islands			Not applicable
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
70 St. Mary Axe London EC3A 8BE United Kingdom (Address of principal executive offices)			Not applicable (Zip Code)

Registrant’s telephone number, including area code: +44 207 4334000

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, no par value	CLVT	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of ordinary shares of the Company outstanding as of June 30, 2025, was 672,219,064.

Table of Contents

TABLE OF CONTENTS


			Page
Part I. Financial Information			4
Item 1. Financial Statements (Unaudited)			4
Condensed Consolidated Balance Sheets			4
Condensed Consolidated Statements of Operations			5
Condensed Consolidated Statements of Comprehensive Income (Loss)			6
Condensed Consolidated Statements of Changes in Equity			7
Condensed Consolidated Statements of Cash Flows			8
Notes to the Condensed Consolidated Financial Statements			9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			20
Item 3. Quantitative and Qualitative Disclosures About Market Risk			28
Item 4. Controls and Procedures			28

Part II. Other Information			28
Item 1. Legal Proceedings			28
Item 1A. Risk Factors			28
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			29
Item 5. Other Information			29
Item 6. Exhibits			30

Signature			31

Table of Contents

Cautionary Note Regarding Forward-Looking Statements

This quarterly report includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the “safe harbor provisions” of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this quarterly report and include statements regarding our intentions, beliefs, or current expectations concerning, among other things, anticipated cost savings, results of operations, financial condition, liquidity, prospects, growth, strategies, and the markets in which we operate. Such forward-looking statements are based on available current market material and management’s expectations, beliefs, and forecasts concerning future events impacting us. Factors that may impact such forward-looking statements include:

•our dependence on third parties, including public sources, for data, information, and other services, and our relationships with such third parties;

•increased accessibility to free or relatively inexpensive information sources;

•our ability to compete in the highly competitive industry in which we operate, and potential adverse effects of this competition;

•our ability to maintain high annual renewal rates;

•our ability to maintain revenues if our products and services do not achieve and maintain broad market acceptance, or if we are unable to keep pace with or adapt to rapidly changing technology, evolving industry standards, macroeconomic market conditions, and changing regulatory requirements;

•changes in government policy positions, including trade policy, spending priorities, or reductions in government programs, government spending, or research funding;

•the success of our Value Creation Plan;

•our loss of, or inability to attract and retain, key personnel;

•the effectiveness of our business continuity plans;

•our ability to derive fully the anticipated benefits from organic growth, existing or future acquisitions, joint ventures, investments, or dispositions;

•our exposure to risk from having operations and employees in Israel;

•our exposure to risk from the international scope of our operations, including potentially adverse tax consequences from the international scope of our operations and our corporate and financing structure;

•the strength of our brand and reputation;

•our level of indebtedness, which could adversely affect our business, financial condition, and results of operations;

•our ability to obtain, protect, defend, or enforce our intellectual property rights;

•our ability to leverage artificial intelligence technologies (“AI”) in our products and services, including generative AI, large language models (“LLMs”), machine learning, and other AI tools;

•any significant disruption in or unauthorized access to or breaches of our computer systems or those of third parties that we utilize in our operations, including those relating to cybersecurity or arising from cyberattacks;

•our use of “open source” software in our products and services;

•our ability to comply with applicable data protection and privacy laws; and

•other factors beyond our control.

The forward-looking statements contained in this quarterly report are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in Item 1A. Risk Factors of this quarterly report and Item 1A. Risk Factors in our most recently filed annual report on Form 10-K. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these

Table of Contents

forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

Defined Terms and Presentation

We employ a number of defined terms in this quarterly report for clarity and ease of reference, which we have capitalized so that you may recognize them as such. As used throughout this quarterly report, unless otherwise indicated or the context otherwise requires, the terms “Clarivate,” the “Company,” “our,” “us,” and “we” refer to Clarivate Plc and its consolidated subsidiaries.

Unless otherwise indicated, dollar amounts throughout this quarterly report are presented in millions of dollars, except for per share amounts.

Website and Social Media Disclosure

We use our website (www.clarivate.com) and corporate social media accounts on Facebook, X, and LinkedIn (@Clarivate) as routine channels of distribution of company information, including news releases, analyst presentations, and supplemental financial information, as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, investors should monitor our website and our corporate Facebook, X, and LinkedIn accounts in addition to following press releases, SEC filings, and public conference calls and webcasts. Additionally, we provide notifications of news or announcements as part of our investor relations website. Investors and others can receive notifications of new information posted on our investor relations website in real time by signing up for email alerts.

None of the information provided on our website, in our press releases, public conference calls, and webcasts, or through social media channels is incorporated into, or deemed to be a part of, this quarterly report or in any other report or document we file with or furnish to the SEC, and any references to our website or our social media channels are intended to be inactive textual references only.

Table of Contents

PART I. Financial Information

Item 1. Financial Statements.

CLARIVATE PLC

Condensed Consolidated Balance Sheets (Unaudited)



(In millions)	June 30, 2025		December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents, including restricted cash	$	362.6	$	295.2

Accounts receivable, net	820.4		798.3
Prepaid expenses	88.5		85.9
Other current assets	68.7		65.2

Total current assets	1,340.2		1,244.6
Property and equipment, net	56.3		53.5
Other intangible assets, net	8,284.0		8,441.2
Goodwill	1,566.9		1,566.6
Other non-current assets	69.5		82.2
Deferred income taxes	51.1		48.5
Operating lease right-of-use assets	53.2		53.6
Total assets	$	11,421.2	$	11,490.2
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	125.7	$	124.5
Accrued compensation	111.4		119.2
Accrued expenses and other current liabilities	292.5		310.1
Current portion of deferred revenues	929.1		859.1
Current portion of operating lease liability	20.1		20.6

Total current liabilities	1,478.8		1,433.5
Long-term debt	4,516.8		4,518.7


Other non-current liabilities	97.4		72.5
Deferred income taxes	284.3		273.3
Operating lease liabilities	49.8		53.2
Total liabilities	6,427.1		6,351.2
Commitments and contingencies (Note 13)
Shareholders' equity:

Ordinary Shares, no par value; unlimited shares authorized; 672.2 and 691.4 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively	12,902.7		12,978.8

Accumulated other comprehensive loss	(419.2)		(526.3)
Accumulated deficit	(7,489.4)		(7,313.5)
Total shareholders' equity	4,994.1		5,139.0
Total liabilities and shareholders' equity	$	11,421.2	$	11,490.2

The accompanying Notes are an integral part of these Condensed Consolidated Financial Statements.

Table of Contents

CLARIVATE PLC

Condensed Consolidated Statements of Operations (Unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
(In millions, except per share data)	2025		2024		2025		2024
Revenues	$	621.4	$	650.3	$	1,215.1	$	1,271.5
Operating expenses:
Cost of revenues	203.6		213.6		410.6		431.4
Selling, general and administrative costs	181.1		185.2		359.5		377.1
Depreciation and amortization	190.9		184.4		376.3		363.8
Goodwill and intangible asset impairments	—		302.8		—		302.8
Restructuring and other impairments	9.3		0.7		34.0		10.2
Other operating expense (income), net	29.6		3.6		48.6		21.2
Total operating expenses	614.5		890.3		1,229.0		1,506.5
Income (loss) from operations	6.9		(240.0)		(13.9)		(235.0)
Fair value adjustment of warrants	—		—		—		(5.2)
Interest expense, net	66.6		71.1		130.9		141.3
Income (loss) before income taxes	(59.7)		(311.1)		(144.8)		(371.1)
Provision (benefit) for income taxes	12.3		(6.8)		31.1		8.2
Net income (loss)	(72.0)		(304.3)		(175.9)		(379.3)
Dividends on preferred shares	—		12.5		—		31.3
Net income (loss) attributable to ordinary shares	$	(72.0)	$	(316.8)	$	(175.9)	$	(410.6)

Per share:
Basic	$	(0.11)	$	(0.46)	$	(0.26)	$	(0.61)
Diluted	$	(0.11)	$	(0.46)	$	(0.26)	$	(0.61)

Weighted average shares used to compute earnings per share:
Basic	681.3		685.6		685.5		676.2
Diluted	681.3		685.6		685.5		676.2

The accompanying Notes are an integral part of these Condensed Consolidated Financial Statements.

Table of Contents

CLARIVATE PLC

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)


	Three Months Ended June 30,
(In millions)	2025		2024
Net income (loss)	$	(72.0)	$	(304.3)
Other comprehensive income (loss), net of tax:
Hedging relationships, net of tax of $(0.6) and $(0.2)	(3.4)		(0.4)
Defined benefit pension plans	0.1		—
Foreign currency translation adjustment	74.7		15.7
Other comprehensive income (loss), net of tax	71.4		15.3
Comprehensive income (loss)	$	(0.6)	$	(289.0)


	Six Months Ended June 30,
(In millions)	2025		2024
Net income (loss)	$	(175.9)	$	(379.3)
Other comprehensive income (loss), net of tax:
Hedging relationships, net of tax of $(1.9) and $0.7	(7.2)		2.2
Defined benefit pension plans	0.1		—
Foreign currency translation adjustment	114.2		(3.9)
Other comprehensive income (loss), net of tax	107.1		(1.7)
Comprehensive income (loss)	$	(68.8)	$	(381.0)

The accompanying Notes are an integral part of these Condensed Consolidated Financial Statements.

Table of Contents

CLARIVATE PLC

Condensed Consolidated Statements of Changes in Equity (Unaudited)


	Ordinary Shares			Preferred Shares			Accumulated Other Comprehensive Loss	Accumulated Deficit		Total Shareholders’ Equity
(In millions)	Shares	Amount		Shares	Amount
Balance at December 31, 2024	691.4	$	12,978.8	—	$	—		$	(526.3)	$	(7,313.5)	$	5,139.0
Vesting of restricted stock units	5.1	—		—	—			—		—		—
Share-based award activity	(1.7)	6.3		—	—			—		—		6.3
Repurchase and retirement of ordinary shares	(11.7)	(50.0)		—	—			—		—		(50.0)
Net income (loss)	—	—		—	—			—		(103.9)		(103.9)
Other comprehensive income (loss)	—	—		—	—			35.7		—		35.7
Balance at March 31, 2025	683.1	$	12,935.1	—	$	—		$	(490.6)	$	(7,417.4)	$	5,027.1
Vesting of restricted stock units	0.8	—		—	—			—		—		—
Share-based award activity	(0.2)	17.1		—	—			—		—		17.1
Repurchase and retirement of ordinary shares	(11.5)	(49.5)		—	—			—		—		(49.5)
Net income (loss)	—	—		—	—			—		(72.0)		(72.0)
Other comprehensive income (loss)	—	—		—	—			71.4		—		71.4
Balance at June 30, 2025	672.2	$	12,902.7	—	$	—		$	(419.2)	$	(7,489.4)	$	4,994.1


	Ordinary Shares			Preferred Shares			Accumulated Other Comprehensive Loss	Accumulated Deficit		Total Shareholders’ Equity
(In millions)	Shares	Amount		Shares	Amount
Balance at December 31, 2023	666.1	$	11,740.5	14.4	$	1,392.6		$	(495.3)	$	(6,645.5)	$	5,992.3

Vesting of restricted stock units	3.3	—		—	—			—		—		—
Share-based award activity	(1.2)	6.9		—	—			—		—		6.9
Dividends to preferred shareholders	—	—		—	—			—		(18.8)		(18.8)
Net income (loss)	—	—		—	—			—		(75.0)		(75.0)
Other comprehensive income (loss)	—	—		—	—			(17.0)		—		(17.0)
Balance at March 31, 2024	668.2	$	11,747.4	14.4	$	1,392.6		$	(512.3)	$	(6,739.3)	$	5,888.4
Vesting of restricted stock units	0.7	—		—	—			—		—		—
Share-based award activity	(0.1)	17.7		—	—			—		—		17.7
Conversion of preferred shares into ordinary shares	55.3	1,392.6		(14.4)	(1,392.6)			—		—		—
Dividends to preferred shareholders	—	—		—	—			—		(12.5)		(12.5)
Net income (loss)	—	—		—	—			—		(304.3)		(304.3)
Other comprehensive income (loss)	—	—		—	—			15.3		—		15.3
Balance at June 30, 2024	724.1	$	13,157.7	—	$	—		$	(497.0)	$	(7,056.1)	$	5,604.6

The accompanying Notes are an integral part of these Condensed Consolidated Financial Statements.

Table of Contents

CLARIVATE PLC

Condensed Consolidated Statements of Cash Flows (Unaudited)


	Six Months Ended June 30,
(In millions)	2025		2024
Cash Flows From Operating Activities
Net income (loss)	$	(175.9)	$	(379.3)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	376.3		363.8
Share-based compensation	29.3		33.9
Restructuring and other impairments, including goodwill	2.2		301.3



Deferred income taxes	(5.4)		(24.6)
Amortization and write-off of debt issuance costs	7.7		7.9
Other operating activities	45.8		14.3
Changes in operating assets and liabilities:
Accounts receivable	2.2		103.2
Prepaid expenses	(1.5)		1.1
Other assets	3.1		(5.4)
Accounts payable	(3.3)		(12.2)
Accrued expenses and other current liabilities	(36.1)		(38.3)
Deferred revenues	42.6		(59.7)
Operating leases, net	(3.2)		(4.8)
Other liabilities	3.7		1.2
Net cash provided by operating activities	287.5		302.4
Cash Flows From Investing Activities
Capital expenditures	(126.9)		(130.3)
Payments for acquisitions, net of cash acquired	—		(17.1)
Proceeds from divestitures, net of cash divested	—		(19.2)
Net cash used for investing activities	(126.9)		(166.6)
Cash Flows From Financing Activities

Principal payments on debt	(500.0)		(52.7)
Proceeds from issuance of debt	500.0		—
Payment of debt issuance costs, extinguishment costs, and related fees	(8.5)		(20.1)
Repurchases of ordinary shares	(99.5)		—
Cash dividends on preferred shares	—		(37.7)
Payments related to tax withholding for share-based compensation	(8.1)		(9.9)
Other financing activities	5.6		(0.4)
Net cash used for financing activities	(110.5)		(120.8)
Effects of exchange rates	17.3		(9.3)
Net change in cash and cash equivalents, including restricted cash	67.4		5.7
Cash and cash equivalents, including restricted cash, beginning of period	295.2		370.7
Cash and cash equivalents, including restricted cash, end of period	$	362.6	$	376.4

The accompanying Notes are an integral part of these Condensed Consolidated Financial Statements.

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)

Note 1: Nature of Operations and Summary of Significant Accounting Policies

Clarivate Plc (“Clarivate,” “us,” “we,” “our,” or the “Company”) is a public limited company incorporated under the laws of Jersey, Channel Islands.

We are a leading global provider of transformative intelligence. We connect people and organizations to the intelligence they can trust to transform their perspective, their work, and our world. We support the entire innovation lifecycle, from cultivating curiosity to protecting the world’s critical intellectual property assets. We offer enriched data, insights & analytics, workflow solutions, and expert services to our customers in the Academia & Government (“A&G”), Intellectual Property (“IP”), and Life Sciences & Healthcare (“LS&H”) end markets, which form the basis of our three reportable segments, organized by the different products and services we offer and the markets we serve. For additional information on our reportable segments, see Note 12 - Segment Information.

Basis of Presentation

The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include our accounts and the accounts of our wholly owned subsidiaries. In our opinion, these interim statements reflect all adjustments necessary to a fair statement of the results for the periods presented, and such adjustments are of a normal, recurring nature. Results from interim periods should not be considered indicative of results for the full year. The financial statements included herein should be read in conjunction with the financial statements and notes included in our annual report on Form 10-K for the year ended December 31, 2024. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. All significant intercompany transactions and balances have been eliminated in consolidation. Cash and cash equivalents is comprised of cash on hand and short-term deposits with an original maturity at the date of purchase of three months or less, and includes restricted cash of $10.3 and $10.5 as of June 30, 2025 and December 31, 2024, respectively.

Certain reclassifications of prior period amounts have been made to conform to the current period presentation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the Condensed Consolidated Financial Statements and accompanying notes. Actual results could differ from those estimates. The most significant of these estimates relate to the initial valuation of acquired long-lived and intangible assets and goodwill, subsequent impairment analyses, and income taxes. We evaluate these estimates, assumptions, and judgments on an ongoing basis by reference to our historical experience and other factors, including worsening macroeconomic and market conditions, sustained declines in our share price, and expectations of future events that we believe are reasonable under the circumstances.

Significant Accounting Policies

Our significant accounting policies are those that we believe are important to the portrayal of our financial condition and results of operations, as well as those that involve significant judgments or estimates about matters that are inherently uncertain. There have been no material changes to the significant accounting policies discussed in Note 1 - Nature of Operations and Summary of Significant Accounting Policies included in Part II, Item 8 of our annual report on Form 10-K for the year ended December 31, 2024.

Recently Issued Accounting Standards

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is designed to provide greater income tax disclosure transparency by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in this update are effective for fiscal years beginning after December 15, 2024 on a prospective basis. We are currently assessing the impact of this update on our related disclosures.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires footnote disclosure that disaggregates relevant expense captions, including the total amount of selling expenses. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027 on a prospective basis, with the option for retrospective application. Early adoption is permitted. We are currently assessing the impact of this update on our financial statement disclosures.

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)

Note 2: Revenues

We provide solutions to our customers primarily through subscription arrangements and re-occurring contracts. We also provide transactional offerings that are typically quoted on a product, data set, or project basis.

•Subscription-based revenues. Recurring revenues that we typically earn under annual contracts, pursuant to which we license the right to use our products to our customers or provide maintenance services over a contractual term. We invoice and collect the subscription fee at the beginning of the subscription period. For multi-year agreements, we generally invoice customers annually at the beginning of each annual coverage period. Cash received or receivable in advance of completing the performance obligations is included in deferred revenue. We recognize subscription revenue ratably over the contractual term as the access or service is provided.

•Re-occurring revenues. Derived from our patent and trademark maintenance services provided to our customers that are renewed regularly. Our services help customers maintain and protect their patents and trademarks in multiple jurisdictions around the world. Because of the re-occurring nature of the patent and trademark lifecycle, our customers engage us to manage the renewal process on their behalf. These contracts typically include evergreen clauses or are multi-year agreements. We invoice and recognize revenue upon delivery of the service.

•Transactional revenues. Earned for specific deliverables that are typically quoted on a product, data set, or project basis. Transactional revenues include content sales (including single-document and aggregated collection sales), consulting engagements, and other professional services such as software implementation services. We typically invoice and record revenue for this revenue stream upon delivery of the product, data set, or project, although for longer software implementation projects, we will periodically invoice and recognize revenue in connection with the completion of related performance obligations.

The following table presents our revenues disaggregated by transaction type (see Note 12 - Segment Information for our revenues disaggregated by segment):


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Subscription revenues	$	405.7	$	405.6	$	794.3	$	808.7
Re-occurring revenues	108.9		108.6		214.8		211.1
Transactional revenues	106.8		136.1		206.0		251.7
Revenues	$	621.4	$	650.3	$	1,215.1	$	1,271.5

The following table presents our contract balances:


	June 30, 2025	December 31, 2024
Accounts receivable, net	820.4	798.3
Current portion of deferred revenues	929.1	859.1
Non-current portion of deferred revenues(1)	17.7	16.6
(1) Included in Other non-current liabilities on the Condensed Consolidated Balance Sheets.

During the six months ended June 30, 2025, we recognized revenues of $546.7 attributable to deferred revenues recorded at the beginning of the period, primarily consisting of subscription revenues recognized ratably over the contractual term.

Our remaining performance obligations are included in the current or non-current portion of deferred revenues on the Condensed Consolidated Balance Sheets. The majority of these obligations relate to customer contracts where we license the right to use our products or provide maintenance services over a contractual term, generally one year or less.

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)

Note 3: Other Intangible Assets, Net

The following table summarizes the gross carrying amounts and accumulated amortization of our identifiable intangible assets by major class:


	June 30, 2025						December 31, 2024
	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
Customer relationships	$	7,850.4	$	(1,703.5)	$	6,146.9	$	7,773.9	$	(1,515.9)	$	6,258.0
Technology and content	2,795.9		(1,333.2)		1,462.7		2,748.8		(1,204.6)		1,544.2
Computer software	1,179.7		(690.8)		488.9		1,060.6		(609.2)		451.4
Trade names and other	89.7		(61.1)		28.6		88.4		(57.7)		30.7
Definite-lived intangible assets	$	11,915.7	$	(3,788.6)	$	8,127.1	$	11,671.7	$	(3,387.4)	$	8,284.3
Indefinite-lived trade names	156.9		—		156.9		156.9		—		156.9
Other intangible assets, net	$	12,072.6	$	(3,788.6)	$	8,284.0	$	11,828.6	$	(3,387.4)	$	8,441.2

Amortization expense related to intangible assets was $185.2 and $179.9 for the three months ended June 30, 2025 and 2024, respectively. For the six months ended June 30, 2025 and 2024, amortization expense was $365.8 and $354.4, respectively.

Note 4: Derivative Instruments

We are exposed to various market risks, including foreign currency exchange rate risk and interest rate risk. We use derivative instruments to manage these risk exposures. We enter into foreign currency contracts and cross-currency swaps to help manage our exposure to foreign currency exchange rate risk and we use interest rate swaps to mitigate interest rate risk. We assess the fair value of these instruments by considering current and anticipated movements in future interest rates and the relevant currency spot and future rates available in the market. Accordingly, these instruments are classified within Level 2 of the fair value hierarchy.

Cash flow hedges

We have interest rate swap arrangements with counterparties to reduce our exposure to variability in cash flows relating to interest payments on our outstanding term loan arrangements. We have designated these swaps as cash flow hedges of the risk associated with floating interest rates on designated future monthly interest payments. As of June 30, 2025, we have two outstanding interest rate swaps entered into in May 2023 with a combined notional value of $745.0, maturing in October 2026, and two swaps entered into in June 2025 with a combined notional value of $402.7, maturing in January 2031. The fair value of the interest rate swaps represents the estimated amount we would receive or pay to terminate such agreements, taking into account market interest rates and the remaining time to maturities or using market inputs with mid-market pricing as a practical expedient for the bid-ask spread.

Changes in fair value are recorded in Accumulated other comprehensive loss (“AOCL”) in the Condensed Consolidated Balance Sheets, with a corresponding adjustment to the derivative asset or liability. Amounts recorded in AOCL are reclassified to Interest expense, net in the same period during which the hedged transactions affect earnings. As of June 30, 2025, we estimate that approximately $7.3 of pre-tax gain related to interest rate swaps recorded in AOCL will be reclassified into earnings within the next 12 months. For additional information on changes recorded in AOCL, see Note 7 - Shareholders' Equity.

Fair value hedges

In June 2025, we entered into two cross-currency swaps with a combined notional value of €350.0, maturing in January 2031, to mitigate foreign currency exposure related to intercompany debt and economically reduce interest expense. We have designated these swaps as fair value hedges. We elected to assess the effectiveness of these hedges based on changes in spot rates.

Changes in fair value are recognized as foreign exchange gains or losses within Other operating expense (income), net, and are intended to offset the foreign exchange gains or losses arising from the remeasurement of the hedged intercompany debt. Unrealized gains or losses on components excluded from the hedge effectiveness assessment are recorded in AOCL and are reclassified into earnings over the life of the swaps. For additional information on changes recorded in AOCL, see Note 7 - Shareholders' Equity.

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)

Net investment hedge

In July 2023, we entered into a €100.0 cross-currency swap maturing in November 2026 to mitigate foreign currency exposure related to our net investment in various euro-functional-currency consolidated subsidiaries. We have designated this swap as a net investment hedge. We elected to assess the effectiveness of this net investment hedge based on changes in spot rates and we amortize the portion of the hedge excluded from the effectiveness assessment to Interest expense, net over the life of the swap.

Changes in fair value related to the effective portion of the hedge are recorded in AOCL as part of the foreign currency translation adjustment, with a corresponding adjustment to the derivative asset or liability. Any accumulated gain or loss will be reclassified into earnings when the hedged net investment is either sold or substantially liquidated. For additional information on changes recorded in AOCL, see Note 7 - Shareholders' Equity.

Derivatives not designated as accounting hedges

We periodically enter into foreign currency forward contracts, generally with maturities of 180 days or less, to reduce our exposure to foreign exchange rate risks. These contracts are not designated as accounting hedges. As of June 30, 2025 and December 31, 2024, the notional amount of our outstanding foreign currency forward contracts was $150.0 and $91.1, respectively.

We initially recognize these contracts at fair value on the execution date and subsequently remeasure them at the end of each reporting period. We determine the fair value of these instruments using market-based inputs, including current and anticipated movements in future interest rates and the relevant currency spot and forward rates. We receive third-party valuation reports to corroborate our determination of fair value.

The gain or loss related to the change in fair value for these contracts is recognized within Other operating expense (income), net. We recognized a (gain) loss from the fair value adjustment of $(1.0) and $0.6 for the three months ended June 30, 2025 and 2024, respectively, and $(3.3) and $2.3 for the six months ended June 30, 2025 and 2024, respectively.

The following table provides the location and the fair value of our derivative instruments in the Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024:


	Balance Sheet Location	June 30, 2025		December 31, 2024
Cash flow hedging relationships:

Interest rate swaps	Other non-current assets	$	7.1	$	14.7

Interest rate swaps	Other non-current liabilities	3.1		—
Fair value hedging relationships:

Cross-currency swaps	Other non-current liabilities	5.9		—

Net investment hedge:

Cross-currency swap	Other non-current assets	—		3.7

Cross-currency swap	Other non-current liabilities	8.7		—
Not designated as accounting hedges:
Foreign currency forwards	Other current assets	2.3		—
Foreign currency forwards	Accrued expenses and other current liabilities	0.1		1.1

Total derivative assets		$	9.4	$	18.4
Total derivative liabilities		$	17.8	$	1.1

Note 5: Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:


	June 30, 2025		December 31, 2024
Liabilities due to customers	$	68.4	$	84.8
Accrued royalties	65.0		79.3
Miscellaneous accruals	159.1		146.0
Accrued expenses and other current liabilities	$	292.5	$	310.1

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)

Note 6: Debt

The following table summarizes our total indebtedness:


		June 30, 2025			December 31, 2024
Type	Maturity	Effective Interest Rate	Carrying Value		Effective Interest Rate	Carrying Value
Senior Secured Notes	2026	4.500%	200.0		4.500%	700.0
Senior Secured Notes	2028	3.875%	921.2		3.875%	921.2
Senior Notes	2029	4.875%	921.4		4.875%	921.4
Revolving Credit Facility	2029	7.077%	—		7.107%	—
Term Loan Facility (Tranche 1)	2031	7.077%	1,999.2		7.107%	1,999.2
Term Loan Facility (Tranche 2)	2031	7.577%	500.0		—%	—
Finance lease	2036	6.936%	28.7		6.936%	29.3
Total debt outstanding			$	4,570.5		$	4,571.1
Debt discounts and issuance costs			(52.3)			(51.1)
Current portion of long-term debt			(1.4)			(1.3)
Long-term debt			$	4,516.8		$	4,518.7

Senior Secured Notes (2026)

Interest on the Senior Secured Notes due 2026 is payable semi-annually to holders of record on May 1 and November 1 of each year. The Senior Secured Notes due 2026 are secured on a first-lien pari passu basis with borrowings under our credit facilities and Senior Secured Notes due 2028. These Notes are guaranteed on a joint and several basis by each of our indirect subsidiaries that is an obligor or guarantor under our credit facilities and are secured on a first-priority basis by the collateral now owned or hereafter acquired by Camelot Finance S.A. (the issuer) and each of the guarantors that secures the issuer’s and such guarantor’s obligations under our credit facilities (subject to permitted liens and other exceptions).

In May 2025, we used the proceeds from the incremental term loans, described below, to redeem $500.0 in aggregate principal amount of the outstanding Senior Secured Notes due 2026, plus accrued and unpaid interest through the redemption date of May 30, 2025.

Senior Secured Notes (2028) and Senior Notes (2029)

Interest on the Senior Secured Notes due 2028 and the Senior Notes due 2029 is payable semi-annually to holders of record on June 30 and December 30 of each year. The Senior Secured Notes due 2028 are secured on a first-lien pari passu basis with borrowings under our credit facilities and Senior Secured Notes due 2026. Both series of notes are guaranteed on a joint and several basis by each of our indirect subsidiaries that is an obligor or guarantor under our credit facilities and Senior Secured Notes due 2026.

The Credit Facilities

Revolving Credit Facility (2029)

Our $700.0 revolving credit facility provides for revolving loans, same-day borrowings, and letters of credit (with a sublimit of $77.0). Proceeds of loans made under the revolving credit facility may be borrowed, repaid, and reborrowed prior to maturity. As of June 30, 2025, letters of credit totaling $6.5 were collateralized by the revolving credit facility.

Term Loan Facility (2031)

Our $2,150.0 Tranche 1 term loans amortize in equal quarterly installments equivalent to a rate of 1.00% per annum, with the remaining balance due at maturity. Optional principal prepayments are applied against the scheduled quarterly installments in the order of upcoming maturities.

In May 2025, we entered into an incremental $500.0 tranche of term loans. These Tranche 2 term loans carry an interest rate margin of 325 basis points per annum in the case of loans bearing interest by reference to term SOFR and are not subject to amortization. The issuance proceeds were used to redeem a portion of the Senior Secured Notes due 2026 described above.

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)

The carrying value of our variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value due to the short-term nature of the interest rate benchmark rates. The fair value of our fixed rate debt is estimated based on market observable data for debt with similar prepayment features. As of June 30, 2025 and December 31, 2024, the fair value of our debt was $4,453.4 and $4,423.2, respectively, and is considered Level 2 under the fair value hierarchy.

Note 7: Shareholders' Equity

Share Repurchase Program

In December 2024, our Board authorized a new share repurchase program of up to $500.0 of our ordinary shares for a period of two years, from January 1, 2025 through December 31, 2026. During the six months ended June 30, 2025, we repurchased approximately 23.2 million ordinary shares for $99.5 at an average price of $4.29 per share. All repurchased shares were immediately retired and restored as authorized but unissued ordinary shares. As of June 30, 2025, we had $400.5 of availability remaining under the share repurchase program.

Accumulated Other Comprehensive Loss (“AOCL”)

The tables below provide information about the changes in AOCL by component and the related amounts reclassified to net earnings during the periods indicated (net of tax).


	Six Months Ended June 30, 2025
	Hedging relationships(1)		Defined benefit pension plans		Foreign currency translation adjustment(2)		AOCL
Balance as of December 31, 2024	$	10.7	$	(0.4)	$	(536.6)	$	(526.3)
Other comprehensive income (loss) before reclassifications	(1.7)		0.1		114.6		113.0
Reclassifications from AOCL to net earnings	(5.5)		—		(0.4)		(5.9)
Net other comprehensive income (loss)	(7.2)		0.1		114.2		107.1
Balance as of June 30, 2025	$	3.5	$	(0.3)	$	(422.4)	$	(419.2)


	Six Months Ended June 30, 2024
	Hedging relationships(1)		Defined benefit pension plans		Foreign currency translation adjustment(2)		AOCL
Balance as of December 31, 2023	$	16.2	$	0.4	$	(511.9)	$	(495.3)
Other comprehensive income (loss) before reclassifications	15.7		—		(3.3)		12.4
Reclassifications from AOCL to net earnings	(13.5)		—		(0.6)		(14.1)
Net other comprehensive income (loss)	2.2		—		(3.9)		(1.7)
Balance as of June 30, 2024	$	18.4	$	0.4	$	(515.8)	$	(497.0)
(1) Includes amounts related to our interest rate swaps designated as cash flow hedges, and for the six months ended June 30, 2025, also includes the excluded component of our cross-currency swaps designated as fair value hedges. Refer to Note 4 - Derivative Instruments for further information.
(2) Primarily includes the impact of translating foreign subsidiary assets and liabilities from their functional currency to USD, and, to a lesser extent, amounts related to our cross-currency swap designated as a net investment hedge.

Conversion of Preferred Shares into Ordinary Shares

On June 3, 2024, all outstanding shares of our 5.25% Series A Mandatory Convertible Preferred Shares (“MCPS”) automatically converted into ordinary shares. All accumulated preferred dividends were paid prior to the conversion.

Note 8: Restructuring and Other Impairments

We have engaged in various restructuring programs to strengthen our business and streamline our operations, including taking actions related to the location and use of leased facilities. Our recent restructuring programs include the following:

•Value Creation Plan - During the fourth quarter of 2024, we approved a broad-based plan to optimize our business model, which includes a cost rationalization component. We expect to incur approximately $5 of additional restructuring costs, primarily from a reduction in workforce, a majority of which we expect to incur in 2025.

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)

•Segment Optimization - During the second quarter of 2023, we approved a restructuring plan to reduce operational costs within targeted areas of the Company, with the primary cost savings driver being from a reduction in workforce. This program is substantially complete.

•ProQuest Acquisition Integration - During the fourth quarter of 2021, we approved a restructuring plan to reduce operational costs within targeted areas of the Company, with the primary cost savings driver being from a reduction in workforce. This program is complete.

The following table summarizes the pre-tax charges by activity and program during the periods indicated:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Severance and related benefit costs:
Value Creation Plan	$	8.8	$	—	$	32.8	$	—
Segment Optimization	—		2.6		0.4		12.1

ProQuest Acquisition Integration	—		—		—		(0.1)
Total Severance and related benefit costs	8.8		2.6		33.2		12.0
Exit and disposal costs:
Value Creation Plan	0.5		—		0.8		—

Segment Optimization	—		0.1		—		0.2

Total Exit and disposal costs	0.5		0.1		0.8		0.2
Lease abandonment costs:


Segment Optimization	—		(2.0)		—		(2.0)

Total Lease abandonment costs	—		(2.0)		—		(2.0)
Restructuring and other impairments	$	9.3	$	0.7	$	34.0	$	10.2

The following table summarizes the pre-tax charges by program and segment during the periods indicated:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Academia & Government:
Value Creation Plan	$	4.3	$	—	$	16.6	$	—
Segment Optimization	—		(0.2)		—		3.8

ProQuest Acquisition Integration	—		—		—		(0.1)
Total A&G	4.3		(0.2)		16.6		3.7
Intellectual Property:
Value Creation Plan	1.8		—		8.0		—

Segment Optimization	—		0.4		0.3		3.0

Total IP	1.8		0.4		8.3		3.0
Life Sciences & Healthcare:
Value Creation Plan	3.2		—		9.0		—

Segment Optimization	—		0.5		0.1		3.5

Total LS&H	3.2		0.5		9.1		3.5
Restructuring and other impairments	$	9.3	$	0.7	$	34.0	$	10.2

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)

The table below summarizes the changes in our restructuring reserves by activity during the periods indicated:


	Severance and related benefit costs		Exit, disposal, and abandonment costs		Total
Reserve balance as of December 31, 2024	$	2.3	$	—	$	2.3
Expenses recorded	33.2		0.8		34.0
Payments made	(27.3)		(0.8)		(28.1)
Noncash items	(2.1)		0.1		(2.0)
Reserve balance as of June 30, 2025	$	6.1	$	0.1	$	6.2

Reserve balance as of December 31, 2023	$	5.9	$	1.4	$	7.3
Expenses recorded	12.0		(1.8)		10.2
Payments made	(15.5)		(2.8)		(18.3)
Noncash items	(0.7)		3.3		2.6
Reserve balance as of June 30, 2024	$	1.7	$	0.1	$	1.8

Note 9: Other Operating Expense (Income), Net

Other operating expense (income), net, consisted of the following:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Loss (gain) on divestiture(1)	$	—	$	(1.0)	$	—	$	14.8

Net foreign exchange loss (gain)	32.7		4.4		53.4		4.6
Miscellaneous expense (income), net	(3.1)		0.2		(4.8)		1.8
Other operating expense (income), net	$	29.6	$	3.6	$	48.6	$	21.2
(1) Related to the sale of Valipat, a small product group within our IP segment.

Note 10: Income Taxes

We compute our provision (benefit) for income taxes by applying the estimated annual effective tax rate to year-to-date pre-tax income (loss) and adjust the provision for discrete tax items recorded in the period.

The income tax provision (benefit) of $12.3 and $(6.8) for the three months ended June 30, 2025 and 2024, respectively, was primarily due to the mix of jurisdictions in which pre-tax profits and losses were recognized and, in the prior year period, a $14.2 tax benefit recorded associated with the goodwill impairment.

The income tax provision (benefit) of $31.1 and $8.2 for the six months ended June 30, 2025 and 2024, respectively, was primarily due to the mix of jurisdictions in which pre-tax profits and losses were recognized and, in the prior year period, an offsetting $14.2 tax benefit associated with the goodwill impairment.

On July 4, 2025, H.R.1, known as the One Big Beautiful Bill Act ("OBBBA"), was enacted into law. OBBBA contains provisions such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to international tax provisions, and the restoration of favorable tax treatment for certain business expenses. We account for income taxes in accordance with ASC Topic 740, Income Taxes, which requires the effects of changes in tax laws and rates to be recognized in the period of enactment. Accordingly, the impacts of OBBBA are not reflected in our results for three and six months ended June 30, 2025. We are currently assessing the impact of OBBBA on our consolidated financial statements and will provide additional disclosures in future periods, as appropriate.

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)

Note 11: Earnings Per Share

The basic and diluted EPS computations for our ordinary shares are calculated as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Basic EPS
Net income (loss)	$	(72.0)	$	(304.3)	$	(175.9)	$	(379.3)
Dividends on preferred shares	—		12.5		—		31.3
Net income (loss) attributable to ordinary shares	$	(72.0)	$	(316.8)	$	(175.9)	$	(410.6)

Weighted average shares, basic	681.3		685.6		685.5		676.2
Basic EPS	$	(0.11)	$	(0.46)	$	(0.26)	$	(0.61)

Diluted EPS


Net income (loss) attributable to ordinary shares, diluted	$	(72.0)	$	(316.8)	$	(175.9)	$	(410.6)


Weighted average shares, basic	681.3		685.6		685.5		676.2
Weighted average effect of potentially dilutive shares	—		—		—		—
Weighted average shares, diluted	681.3		685.6		685.5		676.2
Diluted EPS	$	(0.11)	$	(0.46)	$	(0.26)	$	(0.61)

Potential ordinary shares on a gross basis of 23.5 and 22.5 related to share-based awards and private placement warrants were excluded from diluted EPS for the three months ended June 30, 2025 and 2024, respectively, as their inclusion would have been antidilutive. Potential ordinary shares on a gross basis of 18.8 and 26.2 related to share-based awards and private placement warrants were excluded from diluted EPS for the six months ended June 30, 2025 and 2024, respectively, as their inclusion would have been antidilutive.

As a result of the MCPS conversion described in Note 7 - Shareholders' Equity, during the three and six months ended June 30, 2024, the converted MCPS shares were included in basic EPS for the period subsequent to the conversion. Prior to the conversion, the MCPS shares were evaluated for inclusion in diluted EPS using the if-converted method and, in each period presented, were excluded from diluted EPS as their inclusion would have been antidilutive.

Note 12: Segment Information

As discussed in Note 1 - Nature of Operations and Summary of Significant Accounting Policies, we have organized our business into three reportable segments: Academia & Government, Intellectual Property, and Life Sciences & Healthcare.

Our chief operating decision maker (“CODM”) evaluates performance for our reportable segments based primarily on revenues and Adjusted EBITDA. Adjusted EBITDA represents Net income (loss) before the Provision (benefit) for income taxes, Depreciation and amortization, and Interest expense, net, adjusted to exclude share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in Net income (loss) for the period that we do not consider indicative of our ongoing operating performance.

Significant segment expenses include people-related costs, royalties and other product costs, technology costs (comprised primarily of software licenses and hosting costs), and outside service costs (comprised primarily of professional services and contracted labor). Other costs primarily include facilities costs and product marketing costs.

The following table summarizes reportable segment revenues, expenses, and profit and provides a reconciliation of total reportable segment Adjusted EBITDA to Net income (loss) for the periods indicated:

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Academia & Government
Revenues	$	318.5	$	344.5	$	621.2	$	662.2
People-related costs	(84.1)		(90.5)		(170.3)		(182.7)
Royalties and other product costs	(50.4)		(59.9)		(105.5)		(120.9)
Technology costs	(20.0)		(21.3)		(39.6)		(41.3)
Outside service costs	(8.8)		(10.1)		(17.9)		(20.6)
Other costs	(10.4)		(10.6)		(19.3)		(21.1)
A&G Adjusted EBITDA	$	144.8	$	152.1	$	268.6	$	275.6
Intellectual Property
Revenues	$	202.5	$	201.6	$	395.2	$	402.5
People-related costs	(73.7)		(72.0)		(146.4)		(145.3)
Royalties and other product costs	(19.3)		(16.7)		(37.3)		(38.8)
Technology costs	(12.6)		(12.0)		(24.9)		(23.4)
Outside service costs	(5.2)		(5.0)		(10.9)		(9.8)
Other costs	(7.1)		(6.8)		(12.3)		(13.0)
IP Adjusted EBITDA	$	84.6	$	89.1	$	163.4	$	172.2
Life Sciences & Healthcare
Revenues	$	100.4	$	104.2	$	198.7	$	206.8
People-related costs	(46.2)		(48.2)		(93.0)		(99.0)
Royalties and other product costs	(9.4)		(9.5)		(18.2)		(18.7)
Technology costs	(6.6)		(7.1)		(13.6)		(13.5)
Outside service costs	(3.0)		(3.1)		(5.6)		(6.3)
Other costs	(3.0)		(3.1)		(5.5)		(6.4)
LS&H Adjusted EBITDA	$	32.2	$	33.2	$	62.8	$	62.9
Total Reportable Segments
Revenues	$	621.4	$	650.3	$	1,215.1	$	1,271.5
People-related costs	(204.0)		(210.7)		(409.7)		(427.0)
Royalties and other product costs	(79.1)		(86.1)		(161.0)		(178.4)
Technology costs	(39.2)		(40.4)		(78.1)		(78.2)
Outside service costs	(17.0)		(18.2)		(34.4)		(36.7)
Other costs	(20.5)		(20.5)		(37.1)		(40.5)
Total Reportable Segments Adjusted EBITDA	$	261.6	$	274.4	$	494.8	$	510.7


Benefit (provision) for income taxes	(12.3)		6.8		(31.1)		(8.2)
Depreciation and amortization	(190.9)		(184.4)		(376.3)		(363.8)
Interest expense, net	(66.6)		(71.1)		(130.9)		(141.3)
Share-based compensation expense	(18.5)		(18.9)		(29.6)		(34.3)
Goodwill and intangible asset impairments	—		(302.8)		—		(302.8)
Restructuring and lease impairments	(9.3)		(0.7)		(34.0)		(10.2)
Fair value adjustment of warrants	—		—		—		5.2

Transaction related costs	(8.1)		(3.1)		(14.4)		(7.5)
Other(1)	(27.9)		(4.5)		(54.4)		(27.1)
Net income (loss)	$	(72.0)	$	(304.3)	$	(175.9)	$	(379.3)
(1) Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance. The six months ended June 30, 2024 includes a $14.8 loss on the divestiture described in Note 9 - Other Operating Expense (Income), Net.

Our CODM does not review assets by segment for the purpose of assessing performance or allocating resources due to the significant amount of intangible assets acquired through business combinations, as well as the centralized nature of our working capital management functions.

Table of Contents

CLARIVATE PLC

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In millions or as otherwise noted)

Note 13: Commitments and Contingencies

Lawsuits and Legal Claims

We are engaged in various legal proceedings, claims, audits, and investigations that have arisen in the ordinary course of business. These matters may include among others, antitrust/competition claims, intellectual property infringement claims, employment matters, and commercial matters. The outcome of the matters against us are subject to future resolution, including the uncertainties of litigation.

From time to time, we are involved in litigation in the ordinary course of our business, including claims or contingencies that may arise related to matters occurring prior to our acquisition of businesses. At the present time, primarily because the matters are generally in early stages, we can give no assurance as to the outcome of any pending litigation to which we are currently a party, and we are unable to determine the ultimate resolution of these matters or the effect they may have on us.

We have and will continue to vigorously defend ourselves against these claims. We maintain appropriate levels of insurance, which we expect are likely to provide coverage for some of these liabilities or other losses that may arise from these litigation matters.

Between January and March 2022, three putative securities class action complaints were filed in the United States District Court for the Eastern District of New York against Clarivate and certain of its executives and directors alleging that there were weaknesses in the Company’s internal controls over financial reporting and financial reporting procedures that it failed to disclose in violation of federal securities law. The complaints were consolidated into a single proceeding on May 18, 2022. On August 8, 2022, plaintiffs filed a consolidated amended complaint, seeking damages on behalf of a putative class of shareholders who acquired Clarivate securities between July 30, 2020, and February 2, 2022, and/or acquired Clarivate ordinary or preferred shares in connection with offerings on June 10, 2021, or Clarivate ordinary shares in connection with a September 13, 2021, offering. The amended complaint, like the prior complaints, references an error in the accounting treatment of an equity plan included in the Company’s 2020 business combination with CPA Global that was disclosed on December 27, 2021, and related restatements issued on February 3, 2022, of certain of the Company’s previously issued financial statements. The amended complaint also alleges that the Company and certain of its executives and directors made false or misleading statements relating to the Company’s product quality and expected organic revenues and organic growth rate, and that they failed to disclose significant known changes to the Company’s business model. Defendants moved to dismiss the amended complaint on October 7, 2022. Without deciding the motion, the court entered an order on June 23, 2023, allowing plaintiffs limited leave to amend, and plaintiffs filed an amended complaint on July 14, 2023. On August 10, 2023, the court issued an order deeming defendants’ prior motions and briefs to be directed at the amended complaint and permitting defendants to file supplemental briefs to address the new allegations in the amended complaint. Supplemental briefing on the motions was completed on September 8, 2023. Defendants’ motions to dismiss the amended complaint are currently pending.

In a separate but related litigation, on June 7, 2022, a class action was filed in Pennsylvania state court in the Court of Common Pleas of Philadelphia asserting claims under the Securities Act of 1933, based on substantially similar allegations, with respect to alleged misstatements and omissions in the offering documents for two issuances of Clarivate ordinary shares in June and September 2021. The Company moved to stay this proceeding on August 19, 2022, and filed its preliminary objections to the state court complaint on October 21, 2022. After granting a partial stay on January 4, 2023, the court denied a further stay of the proceedings on April 17, 2023. On April 24, 2024, the court sustained the Company’s preliminary objections, but permitted plaintiff leave to file an amended complaint, which plaintiff filed on May 28, 2024. On August 29, 2024, plaintiff filed a second amended complaint, to which the Company filed preliminary objections on September 30, 2024. On April 25, 2025, the court issued an order permitting the parties to take discovery on issues raised in the Company’s preliminary objections related to standing, and to file supplemental briefs upon completion of such discovery, to be followed by oral argument on the preliminary objections. Clarivate does not believe that the claims alleged in the complaints have merit and will vigorously defend against them. Given the early stage of the proceedings, we are unable to estimate the reasonably possible loss or range of loss, if any, arising from these matters.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion should be read in conjunction with our historical financial statements and related notes included in our annual report on Form 10-K for the year ended December 31, 2024 and the financial statements and related notes included elsewhere in this quarterly report on Form 10-Q. Certain statements in this section are forward-looking statements as described in the Cautionary Note Regarding Forward-Looking Statements of this quarterly report. The risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements include, but are not limited to, factors described in Item 1A. Risk Factors of this quarterly report and Item 1A. Risk Factors in our most recently filed annual report on Form 10-K.

Overview

We are a leading global provider of transformative intelligence. We support the entire innovation lifecycle, from cultivating curiosity to protecting the world’s critical intellectual property assets. Whether it’s providing insights to advance an industry or accelerating the delivery of a critical drug, our vision at Clarivate is to fuel the world’s greatest breakthroughs by harnessing the power of human ingenuity. We offer enriched data, insights & analytics, workflow solutions, and expert services to our customers in the Academia & Government (“A&G”), Intellectual Property (“IP”), and Life Sciences & Healthcare (“LS&H”) end markets, which form the basis of our reportable segment structure. Within each of our three segments, we provide the following:

•Enriched data. Curated, up-to-date content collections validated by skilled data scientists and domain experts with real-world experience.

•Insights & analytics. Predictive analytics powered by a unique combination of AI-enabled software paired with human insights, developed and interpreted by PhD level experts.

•Workflow solutions. Automated, flexible software tools complemented by our enriched data sets and expert analysis tailored to meet specific needs.

•Expert services. We are home to industry specialists, consultants, and data scientists with deep subject-matter expertise and global experience.

Key Performance Indicators

We regularly monitor organic revenue growth, annualized contract value, annual renewal rates, Adjusted EBITDA, Adjusted EBITDA margin, and Free cash flow as key performance indicators that we use to evaluate our business and trends, measure performance, prepare financial projections, and make strategic decisions.

Adjusted EBITDA, Adjusted EBITDA margin, and Free cash flow are financial measures that are not prepared in accordance with U.S. generally accepted accounting principles (“non-GAAP”). Although we believe these measures may be useful to investors in evaluating our business, these measures are not a substitute for GAAP financial measures or disclosures. Reconciliations of our non-GAAP measures to the most directly comparable GAAP measures are provided further below.

Organic revenue growth

We review year-over-year organic revenue growth in our segments as a key measure of our success in addressing customer needs. We also review year-over-year organic revenue growth by transaction type to help us identify and address broad changes in product mix, and by geography to help us identify and address changes and revenue trends by region. We define the components of revenue growth as follows:

•Organic. Revenue generated from pricing, up-selling, securing new customers, sales of new or enhanced product offerings, and any other revenue change drivers except for changes from acquisitions, disposals, and foreign currency.

•Acquisitions. Revenue generated from acquired products and services from the date of acquisition to the first anniversary date of that acquisition.

•Disposals. Revenue generated in the comparative prior year period from product lines, services, and/or businesses divested from the date of the sale in the current period presented or included within a disposal group.

•Foreign Currency (“FX”). The difference between current revenue at current exchange rates and current revenue at the corresponding prior period exchange rates.

Table of Contents

CLARIVATE PLC

Management’s Discussion and Analysis of Financial Condition and Results of Operations

(In millions or as otherwise noted)

Annualized contract value

Our annualized contract value (“ACV”), at any point in time, represents the annualized value of all active customer subscription-based license agreements for the next 12 months, assuming those coming up for renewal during the measurement period are renewed at their current price level. We use ACV as a key indicator of the health and trajectory of our core business as well as to assist in the evaluation of underlying sales execution and customer engagement trends. This metric is particularly important to us because the majority of our revenues are generated from subscription-based license agreements.

Actual subscription revenues that we recognize during any 12-month period are likely to differ from ACV at the beginning of that period, sometimes significantly, due to subsequent changes in volume (including upgrades, downgrades, new business, and cancellations) and price, acquisitions and divestitures, and changes in FX.

Our organic ACV grew 1.3% compared to June 30, 2024, primarily driven by price increases. Our total ACV of $1,535.6 as of June 30, 2025 declined 3.5% compared to $1,591.8 as of June 30, 2024, primarily due to the ScholarOne divestiture in November 2024 and the wind-down of certain product groups beginning in the first quarter of 2025.

Annual renewal rate

Our annual renewal rate, at any point in time, represents (a) the annualized value of all active customer subscription-based license agreements renewed during the measurement period (including the value of any product downgrades), divided by (b) the annualized value of all active subscription-based license agreements that were up for renewal during the measurement period. “Open renewals,” which we define as active customer subscription-based license agreements that were up for renewal during the measurement period but were neither renewed nor canceled, are excluded from both the numerator and denominator of the calculation. Additionally, the impact from product downgrades upon renewal is reflected in the annual renewal calculation, but the impact from product upgrades is not, because upgrades reflect the purchase of additional products and services. The impact of upgrades, new subscriptions, and product price increases is reflected in ACV, but not in annual renewal rates.

As the majority of our revenues are generated from subscription-based license agreements, we use the annual renewal rate as a key indicator of our ability to retain existing customers, evaluate the execution of our sales strategy and customer engagement trends, and to help analyze our historical results and prepare financial projections.

Our annual renewal rate for the six months ended June 30, 2025 and 2024 was 93% and 92%, respectively.

Adjusted EBITDA and Adjusted EBITDA margin

We use Adjusted EBITDA as a basis for evaluating our ongoing operating performance, and we believe it is useful for investors to understand the underlying trends of our operations. Adjusted EBITDA represents Net income (loss) before the Provision (benefit) for income taxes, Depreciation and amortization, and Interest expense, net, adjusted to exclude share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in Net income (loss) for the period that we do not consider indicative of our ongoing operating performance. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by Revenues.

Our presentation of Adjusted EBITDA and Adjusted EBITDA margin should not be construed as an inference that our future results will be unaffected by any of the adjusted items, or that our projections and estimates will be realized in their entirety or at all. In addition, because of these limitations, Adjusted EBITDA should not be considered as a measure of liquidity or discretionary cash available to us to fund our cash needs, including investing in the growth of our business and meeting our obligations. For a reconciliation of Adjusted EBITDA and Adjusted EBITDA margin to Net income (loss) and Net income (loss) margin, refer to Adjusted EBITDA and Adjusted EBITDA margin (non-GAAP measures) below.

Free cash flow

We use Free cash flow in our operational and financial decision-making and believe it is useful to investors because similar measures are frequently used by securities analysts, investors, ratings agencies, and other interested parties to measure the ability of a company to service its debt. Our presentation of Free cash flow should not be considered as a measure of liquidity or discretionary cash available to us to fund our cash needs, including investing in the growth of our business and meeting our obligations. We define Free cash flow as Net cash provided by operating activities less Capital expenditures. For further discussion related to Free cash flow, including a reconciliation to Net cash provided by operating activities, refer to Liquidity and Capital Resources - Cash Flows below.

Table of Contents

CLARIVATE PLC

Management’s Discussion and Analysis of Financial Condition and Results of Operations

(In millions or as otherwise noted)

Results of Operations


	Three Months Ended June 30,				Six Months Ended June 30,				% Change
	2025		2024		2025		2024		QTD	YTD
Revenues	$	621.4	$	650.3	$	1,215.1	$	1,271.5	(4)%	(4)%
Operating expenses:
Cost of revenues	203.6		213.6		410.6		431.4		(5)%	(5)%
Selling, general and administrative costs	181.1		185.2		359.5		377.1		(2)%	(5)%
Depreciation and amortization	190.9		184.4		376.3		363.8		4%	3%
Goodwill and intangible asset impairments	—		302.8		—		302.8		N/M	N/M
Restructuring and other impairments	9.3		0.7		34.0		10.2		N/M	N/M
Other operating expense (income), net	29.6		3.6		48.6		21.2		N/M	N/M
Total operating expenses	614.5		890.3		1,229.0		1,506.5
Income (loss) from operations	6.9		(240.0)		(13.9)		(235.0)
Fair value adjustment of warrants	—		—		—		(5.2)		N/M	N/M
Interest expense, net	66.6		71.1		130.9		141.3		(6)%	(7)%
Income (loss) before income taxes	(59.7)		(311.1)		(144.8)		(371.1)
Provision (benefit) for income taxes	12.3		(6.8)		31.1		8.2		N/M	N/M
Net income (loss)	(72.0)		(304.3)		(175.9)		(379.3)
Dividends on preferred shares	—		12.5		—		31.3		N/M	N/M
Net income (loss) attributable to ordinary shares	$	(72.0)	$	(316.8)	$	(175.9)	$	(410.6)
N/M - Represents a change approximately equal to or in excess of 100% or is not meaningful.

The following factors had a significant impact on the comparability of our results of operations between the periods presented and may affect the comparability of our results of operations in future periods:

•In December 2024, our Board approved the wind-down of three product groups within the LS&H and A&G segments, which is expected to reduce revenues and profit by less than 10% and 5%, respectively.

•In November 2024, we completed the sale of our ScholarOne product group within our A&G segment.

•In the second quarter of 2024, we recognized a substantial goodwill impairment.

•In April 2024, we completed the sale of our Valipat product group within our IP segment.

Revenues

The following tables present our revenues by type, segment, and geography, as well as the components driving the changes between periods.

Revenues by transaction type


	Three Months Ended June 30,				Change				% of Change
	2025		2024		$		%		Acquisitions		Disposals		FX		Organic
Subscription	$	405.7	$	405.6	$	0.1	—	%	0.1	%	(3.1)	%	1.3	%	1.7	%
Re-occurring	108.9		108.6		0.3		0.3	%	—	%	—	%	2.6	%	(2.3)	%
Recurring revenues	514.6		514.2		0.4		0.1	%	0.1	%	(2.4)	%	1.6	%	0.8	%
Transactional	106.8		136.1		(29.3)		(21.5)	%	—	%	(21.1)	%	1.0	%	(1.4)	%
Revenues	$	621.4	$	650.3	$	(28.9)	(4.4)	%	0.1	%	(6.4)	%	1.4	%	0.5	%

Subscription revenues were flat, as organic growth, driven by new sales and price increases, and FX translation gains were offset by disposal-related reductions, primarily from the ScholarOne product group divestiture and product group wind-downs within LS&H. Re-occurring revenues increased modestly due to FX translation gains that were partially offset by lower IP patent renewal volumes. Transactional revenues decreased primarily due to product group wind-downs within A&G.

Table of Contents

CLARIVATE PLC

Management’s Discussion and Analysis of Financial Condition and Results of Operations

(In millions or as otherwise noted)


	Six Months Ended June 30,				Change				% of Change
	2025		2024		$		%		Acquisitions		Disposals		FX		Organic
Subscription	$	794.3	$	808.7	$	(14.4)	(1.8)	%	0.2	%	(2.8)	%	0.2	%	0.6	%
Re-occurring	214.8		211.1		3.7		1.8	%	—	%	—	%	0.4	%	1.4	%
Recurring revenues	1,009.1		1,019.8		(10.7)		(1.0)	%	0.2	%	(2.1)	%	0.2	%	0.7	%
Transactional	206.0		251.7		(45.7)		(18.2)	%	0.1	%	(16.7)	%	0.2	%	(1.8)	%
Revenues	$	1,215.1	$	1,271.5	$	(56.4)	(4.4)	%	0.1	%	(5.2)	%	0.3	%	0.4	%

Subscription revenues decreased due to the ScholarOne product group divestiture and product group wind-downs within LS&H, partially offset by organic growth driven by new sales and price increases. Re-occurring revenues increased primarily due to higher IP patent renewal volumes. Transactional revenues decreased primarily due to the Valipat product group divestiture and product group wind-downs within A&G.

Revenues by segment


	Three Months Ended June 30,				Change				% of Change
	2025		2024		$		%		Acquisitions		Disposals		FX		Organic
A&G	$	318.5	$	344.5	$	(26.0)	(7.5)	%	—	%	(11.0)	%	1.0	%	2.5	%
IP	202.5		201.6		0.9		0.4	%	0.2	%	—	%	2.3	%	(2.1)	%
LS&H	100.4		104.2		(3.8)		(3.6)	%	0.2	%	(5.3)	%	1.2	%	0.3	%
Revenues	$	621.4	$	650.3	$	(28.9)	(4.4)	%	0.1	%	(6.4)	%	1.4	%	0.5	%

A&G segment revenues decreased, as subscription growth driven by new sales and price increases, was offset by the ScholarOne product group divestiture and product group wind-downs. IP segment revenues increased modestly, primarily due to FX translation gains, partially offset by lower IP transactional volumes. LS&H segment revenues decreased primarily due to product group wind-downs.


	Six Months Ended June 30,				Change				% of Change
	2025		2024		$		%		Acquisitions		Disposals		FX		Organic
A&G	$	621.2	$	662.2	$	(41.0)	(6.2)	%	—	%	(7.9)	%	0.1	%	1.6	%
IP	395.2		402.5		(7.3)		(1.8)	%	0.2	%	(2.0)	%	0.4	%	(0.4)	%
LS&H	198.7		206.8		(8.1)		(3.9)	%	0.5	%	(3.2)	%	0.2	%	(1.4)	%
Revenues	$	1,215.1	$	1,271.5	$	(56.4)	(4.4)	%	0.1	%	(5.2)	%	0.3	%	0.4	%

A&G segment revenues decreased, as subscription growth, driven by new sales and price increases, was offset by the ScholarOne product group divestiture and product group wind-downs. IP segment revenues decreased primarily due to the Valipat product group divestiture. LS&H segment revenues decreased primarily due to product group wind-downs and lower subscription revenues.

Revenues by geography


	Three Months Ended June 30,				Change				% of Change
	2025		2024		$		%		Acquisitions		Disposals		FX		Organic
Americas	$	331.9	$	354.9	$	(23.0)	(6.5)	%	0.2	%	(7.5)	%	0.3	%	0.5	%
EMEA	164.9		170.0		(5.1)		(3.0)	%	—	%	(7.3)	%	3.4	%	0.9	%
APAC	124.6		125.4		(0.8)		(0.6)	%	—	%	(2.6)	%	1.9	%	0.1	%
Revenues	$	621.4	$	650.3	$	(28.9)	(4.4)	%	0.1	%	(6.4)	%	1.4	%	0.5	%

Americas revenues decreased primarily due to the ScholarOne divestiture and product group wind-downs within A&G and LS&H. EMEA (Europe/Middle East/Africa) revenues decreased primarily due to the ScholarOne product group divestitures and product group wind-downs within A&G. APAC (Asia Pacific) revenues decreased due to product group wind-downs within A&G.

Table of Contents

CLARIVATE PLC

Management’s Discussion and Analysis of Financial Condition and Results of Operations

(In millions or as otherwise noted)


	Six Months Ended June 30,				Change				% of Change
	2025		2024		$		%		Acquisitions		Disposals		FX		Organic
Americas	$	653.0	$	685.2	$	(32.2)	(4.7)	%	0.3	%	(5.5)	%	(0.1)	%	0.6	%
EMEA	316.6		338.5		(21.9)		(6.5)	%	—	%	(7.1)	%	0.9	%	(0.3)	%
APAC	245.5		247.8		(2.3)		(0.9)	%	—	%	(2.1)	%	0.2	%	1.0	%
Revenues	$	1,215.1	$	1,271.5	$	(56.4)	(4.4)	%	0.1	%	(5.2)	%	0.3	%	0.4	%

Americas revenues decreased primarily due to the ScholarOne divestiture and product group wind-downs within A&G and LS&H. EMEA revenues decreased primarily due to the Valipat and ScholarOne product group divestitures and product group wind-downs within A&G. APAC revenues decreased due to product group wind-downs within A&G, partially offset by A&G subscription growth.

Cost of revenues

Cost of revenues consists of costs related to the production, servicing, and maintenance of our products and are composed primarily of related personnel costs, data center services and licensing costs, and costs to acquire or produce content, including royalty fees.

The decrease of 4.7% and 4.8% compared to the three and six months ended June 30, 2024, respectively, was primarily driven by product group wind-downs within A&G and cost management. As a percentage of revenues, cost of revenues were largely unchanged compared to the respective comparative prior year periods.

Selling, general and administrative costs

Selling, general and administrative (“SG&A”) costs include nearly all business costs not directly attributable to the production, servicing, and maintenance of our products and are composed primarily of personnel costs, third-party professional services fees, facility costs like rent and utilities, technology costs associated with our corporate infrastructure, and transaction expenses associated with acquisitions, divestitures, and capital market activities including advisory, legal, and other professional and consulting costs.

The decrease of 2.2% and 4.7% compared to the three and six months ended June 30, 2024, respectively, was primarily driven by cost management and reductions in share-based compensation expense. As a percentage of revenues, SG&A costs were largely unchanged compared to the respective comparative prior year periods.

Depreciation and amortization

Depreciation expense relates to our fixed assets, including computer hardware, leasehold improvements, and furniture and fixtures. Amortization expense relates to our definite-lived intangible assets, including customer relationships, technology and content, internally developed computer software, and trade names.

The increase of 3.5% and 3.4% compared to the three and six months ended June 30, 2024, respectively, was primarily driven by increased investment in content assets.

Goodwill and intangible asset impairments

In the second quarter of 2024, primarily due to sustained declines in our share price, we performed an interim quantitative goodwill impairment assessment by comparing the estimated fair value to the carrying value for both of our segment reporting units carrying a goodwill balance. The carrying value of the LS&H segment reporting unit exceeded its fair value, resulting in a goodwill impairment charge of $302.8.

Restructuring and other impairments

Restructuring and other impairment expense includes costs associated with certain involuntary termination benefits, contract terminations, and other exit or disposal activities.

Charges for the three and six months ended June 30, 2025 were primarily associated with the Value Creation Plan, which began in the fourth quarter of 2024 and is expected to be substantially completed by the end of 2025. Charges for the three and six months ended June 30, 2024 were primarily associated with the Segment Optimization Program, which was substantively completed in 2024. For further information regarding each of our restructuring initiatives and impairment impacts, see Note 8 - Restructuring and Other Impairments included in Part I, Item 1 of this quarterly report.

Table of Contents

CLARIVATE PLC

Management’s Discussion and Analysis of Financial Condition and Results of Operations

(In millions or as otherwise noted)

Other operating expense (income), net

The change of $26.0 compared to the three months ended June 30, 2024 was driven by the net impact of realized and unrealized gains and losses on foreign currency transactions, with the largest impacts derived from transactions denominated in GBP.

The change of $27.4 compared to the six months ended June 30, 2024 was driven by the net impact of realized and unrealized gains and losses on foreign currency transactions, with the largest impacts derived from transactions denominated in GBP, offset by a $14.8 loss on divestiture in the prior year period. For further information, see Note 9 - Other Operating Expense (Income), Net included in Part I, Item 1 of this quarterly report.

Interest expense, net

The decrease of 6.3% and 7.4% compared to the three and six months ended June 30, 2024, respectively, was driven by lower interest rates on our outstanding variable-rate debt and reduced borrowings under our notes and credit facilities.

Provision (benefit) for income taxes

The current quarter effective tax rate may not be indicative of our effective tax rates for future periods.

In December 2021, the Organization for Economic Co-operation and Development (“OECD”) issued model rules for a new global minimum tax framework under its “Pillar Two” initiative, and various governments around the world have issued, or have announced that they plan to issue, legislation consistent with the OECD model rules. We are within the scope of the OECD Pillar Two model rules.

During the third quarter of 2023, the United Kingdom enacted legislation consistent with the OECD model rules, which became effective January 1, 2024. Based on our most recent tax filings, country-by-country reporting, and financial information available, we believe that most of the jurisdictions in which we operate will meet the requirements for transitional safe harbor relief. Therefore, we do not expect the global minimum tax to have a material impact in 2025. However, future legislation or changes in our financial results could materially increase our global minimum tax expense.

Table of Contents

CLARIVATE PLC

Management’s Discussion and Analysis of Financial Condition and Results of Operations

(In millions or as otherwise noted)

Adjusted EBITDA and Adjusted EBITDA margin (non-GAAP measures)

The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA margin for the three and six months ended June 30, 2025 and 2024, and reconciles these non-GAAP measures to our Net income (loss) and Net income (loss) margin for the same periods:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Net income (loss)	$	(72.0)	$	(304.3)	$	(175.9)	$	(379.3)
Provision (benefit) for income taxes	12.3		(6.8)		31.1		8.2
Depreciation and amortization	190.9		184.4		376.3		363.8
Interest expense, net	66.6		71.1		130.9		141.3
Share-based compensation expense	18.5		18.9		29.6		34.3
Goodwill and intangible asset impairments	—		302.8		—		302.8
Restructuring and other impairments	9.3		0.7		34.0		10.2
Fair value adjustment of warrants	—		—		—		(5.2)
Transaction related costs	8.1		3.1		14.4		7.5

Other(1)	27.9		4.5		54.4		27.1
Adjusted EBITDA	$	261.6	$	274.4	$	494.8	$	510.7

Net income (loss) margin	(11.6)%		(46.8)%		(14.5)%		(29.8)%
Adjusted EBITDA margin	42.1%		42.2%		40.7%		40.2%
(1) Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance. The six months ended June 30, 2024 includes a $14.8 loss on the divestiture described in Note 9 - Other Operating Expense (Income), Net.

Liquidity and Capital Resources

We finance our operations primarily through cash generated by operating activities and through borrowing activities. As of June 30, 2025, we had $362.6 of cash and cash equivalents (including restricted cash of $10.3) and $693.5 of available borrowing capacity under our revolving credit facility.

Cash Flows

We have historically generated significant cash flows from our operating activities. Our subscription-based revenue model provides a steady and predictable source of revenue and cash flow for us, as we typically receive payments from our customers at the start of the subscription period (usually 12 months) and recognize revenue ratably throughout that period. Our high customer renewal rate, stable margins, and efforts to improve operating efficiencies and working capital management also contribute to our ability to generate solid operating cash flows.

The following table discloses our cash flows by activity for the periods presented:


	Six Months Ended June 30,				Change
	2025		2024		$	%
Net cash provided by operating activities	$	287.5	$	302.4	(14.9)	(5)	%
Net cash used for investing activities	$	(126.9)	$	(166.6)	39.7	(24)	%
Net cash used for financing activities	$	(110.5)	$	(120.8)	10.3	(9)	%

The decrease in net cash provided by operating activities was primarily due to an increase in restructuring costs.

The decrease in net cash used for investing activities was primarily due to cash used for acquisition and divestiture activity in the prior year period and lower capital spending in the current year.

The decrease in net cash used for financing activities was primarily due to payments on our term loans and MCPS dividends in the prior year period, offset by an increase in cash used to repurchase our ordinary shares in the current year.

Table of Contents

CLARIVATE PLC

Management’s Discussion and Analysis of Financial Condition and Results of Operations

(In millions or as otherwise noted)

Free cash flow (non-GAAP measure)

The following table reconciles our non-GAAP Free cash flow measure to Net cash provided by operating activities for the periods presented:


	Six Months Ended June 30,				Change
	2025		2024		$		%
Net cash provided by operating activities	$	287.5	$	302.4	$	(14.9)	(5)	%
Capital expenditures	(126.9)		(130.3)		3.4		(3)	%
Free cash flow	$	160.6	$	172.1	$	(11.5)	(7)	%

Free cash flow decreased due to the change in net cash provided by operating activities described above, partially offset by a slight reduction in capital expenditures. Our capital expenditures in both periods presented consisted primarily of capitalized labor, contract services, and other costs associated with product and content development.

Borrowings

As of June 30, 2025, we had $4,541.8 of outstanding borrowings under our notes and credit facilities. We incurred $130.9 and $141.3 of interest expense associated with our debt obligations during the six months ended June 30, 2025 and 2024, respectively. Our contingent liabilities consist primarily of letters of credit and performance bonds and other similar obligations in the ordinary course of business.

In May 2025, we entered into an incremental $500.0 tranche of term loans under our term loan facility. These term loans carry an interest rate margin of 325 basis points per annum in the case of loans bearing interest by reference to term SOFR and are not subject to amortization. We used the issuance proceeds to redeem $500.0 aggregate principal amount of our outstanding Senior Secured Notes due 2026, plus accrued and unpaid interest through the redemption date of May 30, 2025. To offset the incremental interest expense impact of this refinancing, we entered into foreign currency swap transactions to effectively convert approximately 80% of the new term loan debt from U.S. dollars to Euro, economically reducing the interest rate by approximately 2%. For further discussion related to our outstanding borrowings and associated hedging activities, see Note 6 - Debt and Note 4 - Derivative Instruments included in Part I, Item 1 of this quarterly report.

Commitments and Contingencies

In addition to the scheduled future debt repayments that we will need to make, we also have commitments and plans related to our share repurchase program, capital expenditures, and other commitments in the ordinary course of business, primarily for cloud computing services and software license costs. Any amounts for which we are currently liable are reflected in our Condensed Consolidated Balance Sheets as Accounts payable or Accrued expenses and other current liabilities.

As of June 30, 2025, we had $400.5 of availability remaining under our current share repurchase program. The share repurchase authorization is valid through December 31, 2026. The share repurchase program does not obligate us to repurchase any set dollar amount or number of shares and may be modified, suspended, or terminated at any time without prior notice. Under the share repurchase program, we are authorized to conduct open-market purchases of our ordinary shares from time to time through any method or program, including through Rule 10b5-1 trading plans or the use of other techniques as permitted by our shareholder authorization, approved by our Board of Directors or a designated committee thereof, and subject to availability of ordinary shares, price, market conditions, alternative uses of capital, and applicable regulatory requirements, at management’s discretion.

In addition, we are engaged in various legal proceedings and claims that have arisen in the ordinary course of business and have taken what we believe to be adequate reserves related to the litigation and threatened claims. We maintain appropriate insurance policies in place, which are likely to provide some coverage for these liabilities or other losses that may arise from litigation matters. For additional information about our legal proceedings and claims, see Note 13 - Commitments and Contingencies included in Part I, Item 1 of this quarterly report.

We require and will continue to need significant cash resources to, among other things, meet our debt service requirements, fund our working capital requirements, make capital expenditures (including product and content development), and expand our business through acquisitions. Based on our forecasts, we believe that cash flow from operations, available cash on hand, borrowing capacity, and access to capital markets will be adequate to service debt, meet liquidity needs, and fund capital expenditures and other business plans for both the next 12 months and the foreseeable future. Our future capital requirements will depend on many factors, including the number of future acquisitions and the timing and extent of spending to support

Table of Contents

CLARIVATE PLC

Management’s Discussion and Analysis of Financial Condition and Results of Operations

(In millions or as otherwise noted)

product development efforts. We could be required, or could elect, to seek additional funding through public or private equity or debt financings; however, additional funds may not be available on terms acceptable to us.

Critical Accounting Policies and Estimates

There have been no material changes to our critical accounting policies and estimates from those reported under Part I, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates in our annual report on Form 10-K for the year ended December 31, 2024.

Recently Issued and Adopted Accounting Pronouncements

For recently issued and adopted accounting pronouncements, see Note 1 - Nature of Operations and Summary of Significant Accounting Policies included in Part I, Item 1 of this quarterly report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Market risk is the risk that changes in market prices, such as foreign currency exchange rates and interest rates, will affect our cash flows or the fair value of our holdings of financial instruments. Market risks as of June 30, 2025 have not materially changed from those discussed under Part I, Item 7A. Quantitative and Qualitative Disclosures About Market Risk in our annual report on Form 10-K for the year ended December 31, 2024.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Pursuant to Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act, we have evaluated, under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act as of the end of the period covered by this report. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of our controls and procedures relative to their costs.

Based on that evaluation, our CEO and CFO concluded that, as of June 30, 2025 our disclosure controls and procedures were effective at the reasonable assurance level to ensure that the information required to be disclosed in the reports required to be filed or submitted under the Securities Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2025 that materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

PART II. Other Information

Item 1. Legal Proceedings.

For information related to legal proceedings, see Note 13 - Commitments and Contingencies included in Part I, Item 1 of this quarterly report.

Item 1A. Risk Factors.

There have been no material changes to the risk factors associated with our business from those reported under Part I, Item 1A. Risk Factors in our annual report on Form 10-K for the year ended December 31, 2024.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Issuer Purchases of Equity Securities

The following table sets forth the total number of shares purchased, the average price paid per share, the total number of shares purchased as part of publicly announced programs, and the approximate dollar value of shares that may yet be purchased under the programs for each month during the three months ended June 30, 2025.


Period	Total Number of Shares Purchased(1)	Average Price Paid Per Share		Total Number of Shares Purchased As Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares That May Yet Be Purchased Under Plans or Programs(2)
April 1, 2025 - April 30, 2025	50,068	$	3.44	—	$	450
May 1, 2025 - May 31, 2025	1,145,893	$	4.24	1,057,743	$	446
June 1, 2025 - June 30, 2025	10,472,195	$	4.30	10,458,032	$	401



Total	11,668,156			11,515,775
(1) Includes shares withheld to satisfy tax withholding obligations on behalf of employees that occur upon vesting and delivery of outstanding shares underlying equity awards under the Amended and Restated 2019 Incentive Award Plan.
(2) In December 2024, our Board of Directors authorized a share repurchase program of up to $500.0 for a period of two years, from January 1, 2025 through December 31, 2026. On May 7, 2025, we obtained shareholder approval updating our previous shareholder share repurchase authority. The updated authority allows us to conduct open-market purchases, as approved by our Board of Directors, of up to 100 million of our ordinary shares from time to time through May 6, 2030, at a purchase price of no less than $1 per share and no more than $35 per share.

Item 5. Other Information.

During the quarter ended June 30, 2025, no director or officer (as defined in Rule 16a-1 under the Exchange Act) of the Company adopted or terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408(a) of Regulation S-K).

Table of Contents

Item 6. Exhibits.

EXHIBIT INDEX


10.1*+			Clarivate Plc Amended and Restated 2019 Incentive Award Plan dated as of June 1, 2025
10.2*+			Clarivate Plc Amended and Restated 2019 Incentive Award Plan – Form of Restricted Share Unit Agreement (2025)
10.3*+			Clarivate Plc Amended and Restated 2019 Incentive Award Plan – Form of Restricted Share Unit Agreement – Non-Executive Directors (2025)
10.4*+			Clarivate Plc Amended and Restated 2019 Incentive Award Plan – Form of Performance Share Unit Agreement (2025)
10.5			Amendment No. 7 dated as of May 30, 2025 to Credit Agreement dated as of October 31, 2019 (incorporated by reference to Exhibit 10.1 to Clarivate’s Form 8-K filed June 2, 2025)
31*			Certification of our Chief Executive Officer and our Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32*			Certification of our Chief Executive Officer and our Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*			The following information from our Form 10-Q for the quarter ended June 30, 2025, formatted in Inline Extensible Business Reporting Language: (i) Condensed Consolidated Balance Sheets (Unaudited), (ii) Condensed Consolidated Statements of Operations (Unaudited), (iii) Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited), (iv) Condensed Consolidated Statements of Changes in Equity (Unaudited), (v) Condensed Consolidated Statements of Cash Flows (Unaudited), and (vi) Notes to the Condensed Consolidated Financial Statements (Unaudited).
104*			Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

* Filed herewith.

+ Compensatory plan or arrangement.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized in the City of London, United Kingdom on July 30, 2025.


CLARIVATE PLC
By:			/s/ Jonathan M. Collins
			Name: Jonathan M. Collins
			Title: Executive Vice President & Chief Financial Officer



Participant:
Employee ID:
Grant Number:
Grant Date:
Number of RSUs:
Vesting Schedule:	Subject to (i) the acceptance of the Agreement by the Participant; (ii) the terms of the Agreement; and (iii) the Participant’s continued employment with the Company through each applicable vesting date, the RSUs shall vest as follows:
Number of RSUs:		Vesting Date:


Participant:
Grant Date:
Grant Number:
Number of RSUs:
Vesting Schedule:			Subject to the terms of the Agreement, including the Participant’s continued Service with the Company through the vesting date, the RSUs shall vest 100% on the date immediately preceding the Company’s next Annual General Meeting of Shareholders.


Participant:
Employee ID:
Grant Number:
Grant Date:
Number of PSUs granted at “Target” performance level (Target Number of Units Granted):
Vesting Schedule:			PSUs shall vest as set forth in Article II of the Agreement
Performance Measures			Adjusted EPS (⅓), Adjusted EBITDA (⅓) and Recurring Organic Revenue Growth (⅓) for the Measurement Period, with a Three-Year TSR Modifier applied to the Achievement Level Percent, as set forth in Article II of the Agreement.


Date: July 30, 2025			/s/ Matitiahu Shem Tov
			Matitiahu Shem Tov
			Chief Executive Officer and Director


Date: July 30, 2025			/s/ Matitiahu Shem Tov
			Matitiahu Shem Tov
			Chief Executive Officer and Director


CLARIVATE PLC AMENDED AND RESTATED 2019 INCENTIVE AWARD PLAN (As Amended and Restated as of June 1, 2025)


CLARIVATE PLC AMENDED AND RESTATED 2019 INCENTIVE AWARD PLAN


(i)			Except in connection with the faithful performance of Participant’s duties as a Service Provider or pursuant to Section 4.1(a)(iii), Section 4.1(a)(iv) or Section 4.2, Participant shall, in perpetuity, maintain in confidence and shall not directly, indirectly or otherwise, use, disseminate, disclose or publish, or use for Participant’s benefit or the benefit of any person, firm, corporation or other entity (other than the Company or any Subsidiary) any Confidential Information or Trade Secrets, or deliver to any person, firm, corporation or other entity any document, record, notebook, computer program or similar repository of or containing any such Confidential Information or Trade Secrets. For purposes of this Agreement, “Confidential Information” shall mean information that the Company or its Subsidiaries have obtained in connection with its present or planned business, including information Participant developed in the performance of Participant’s service as a Service Provider, the disclosure of which could result in a competitive or other disadvantage to the Company or its Subsidiaries. “Confidential Information” includes some of the Company’s and its Subsidiaries’ most valuable assets, such as: innovations, inventions and ideas, including patentable or copyrightable subject matter; pricing policies; business plans and outlooks; brand formulations; nonpublic financial results; new product developments or plans; customer lists; author or consultant contracts; subscription lists; software or computer programs; merger, acquisition or divestiture plans; personnel acquisition plans or major management changes; and Trade Secrets (as defined below). Confidential Information includes all information received by the Company or its Subsidiaries under an obligation of confidentiality to another person or entity. The Participant and the Company and its Subsidiaries hereby stipulate and agree that, as between them, any item of Confidential Information or Trade Secrets is important, material and confidential and affects the successful conduct of the businesses of the Company and its Subsidiaries (and any successor or assignee of the Company and its Subsidiaries). Notwithstanding the foregoing, Confidential Information shall not include any information that (i) has been published or is in the future published in a form generally available to the public, (ii) is or becomes publicly available or (iii) has become or becomes public knowledge prior to the date Participant proposes to disclose or use such information; provided that such publishing or public availability or knowledge of the Confidential Information shall not have resulted from Participant directly or indirectly breaching Participant’s obligations under this Section 4.1(a) or any other similar provision by which Participant is bound. For the purposes of the previous sentence, Confidential Information will not be deemed to have been published or otherwise disclosed merely because individual portions of the information have been separately published, but only if material features comprising such information have been published or become publicly available. For purposes of this Agreement, “Trade Secrets” shall mean all forms and types of financial, business, scientific, technical, economic or engineering information, including patterns, plans, compilations, program devices, formulas, designs, prototypes, methods, techniques, processes, procedures, programs or codes, whether tangible or intangible, and whether or how stored, compiled or memorialized physically, electronically, graphically, photographically or in writing by the Company or its Subsidiaries. The Company confirms, and Participant understands, that the Company or a Subsidiary is the owner of its Trade Secrets, that the Company or its Subsidiary has taken reasonable steps, under the circumstances, to protect and maintain the secrecy of its Trade Secrets, and that the Company or its Subsidiary derives economic value, both tangible and intangible, from its Trade Secrets.
(ii)			Upon the Participant’s Termination of Service for any reason, Participant will promptly deliver to the Company all correspondence, drawings, manuals, letters, notes, notebooks, reports, programs, plans, proposals, financial documents, or any other documents or property concerning the Company’s or any Subsidiary’s customers, business plans, marketing strategies, products, property or processes.
(iii)			Participant may respond to a lawful and valid subpoena or other legal process but shall (i) give the Company the earliest possible notice thereof, (ii) as much in advance of the return date as possible, make available to the Company and its counsel the documents and other information sought and (iii) assist such counsel at the Company’s expense in resisting or otherwise responding to such process, in each case, to the extent permitted by Applicable Laws or rules.
(iv)			Nothing in this Agreement shall prohibit Participant from (i) disclosing information and documents when required by law, subpoena or court order (subject to the requirements of Section 4.1(a)(iii) above), (ii) disclosing information and documents to Participant’s attorney or financial or tax advisor for the purpose of securing legal, financial or tax advice, (iii) disclosing Participant’s post-service restrictions in this Agreement in confidence to any potential new service recipient, or (iv) retaining, at any time, Participant’s personal correspondence, Participant’s personal contacts and documents related to Participant’s own personal benefits, entitlements and obligations.


Section 4.2			Whistleblower Protection; Defend Trade Secrets Act.


Date: July 30, 2025			/s/ Jonathan M. Collins
			Jonathan M. Collins
			Executive Vice President and Chief Financial Officer